Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT). Nearly two million men are receiving ADT, a palliative treatment for

Embarrassing and sometimes uncomfortable colonoscopies may soon be a thing of the past. National researchers are taking note of a new screening test that is making its way through the approval process.

A relatively minor change in treatment of some breast cancers may save thousands of lives yearly, a Mayo Clinic researcher is announcing this weekend. About 25 percent of breast cancers make too much of the protein known as HER2. Dr.

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T- DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent

Doctors at a San Antonio symposium found a new protocol for treating breast cancer shows possibly paradigm-shifting results, they say.

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

Nanosensors, a blood-based technology, can spot early signs of cancer, according to a new study. By taking everyday blood samples from patients, the device can lead to quicker detection and treatment, said the study, whose findings were published online Dec.

U.S. scientists say they've found adding a small molecule to the chemotherapy drug Temozolomide hikes its effectiveness at a much smaller dosage.

U.S. medical researchers say they've developed an experimental cancer drug that kills breast tumor cells that survive chemotherapy. Dr. Jenny Chang of the Baylor College of Medicine and a lead investigator of the research, along with scientists from the University

HealthLeaders-InterStudy and Fingertip Formulary find that over the next five years, a greater percentage of health plans will transition orally delivered oncology drugs from a copayment structure to a reimbursement model that incorporates a coinsurance payment, thereby shifting more costs